micro2MACRO (m2M) has been launched, in December 2024 and the official kick-off in January 2025, with the goal of advancing tissue regeneration through the development of an innovative bioprinting platform. This project will bring together leading academic institutions, research centers, and companies to create a system for producing personalised, scalable grafts that can support the repair of damaged tissues.
The project will focus on the controlled, reliable, and precise patterning cellular aggregates and microtissues into large, customizable grafts with programmed structures. The main objective is to develop a platform capable of positioning multiple cellular aggregates or microtissues into stable, durable grafts that can be remodelled into functional tissues once implanted into the body.
Led by a collaborative group of partners, Trinity College Dublin, the coordinator of the project, University Medical Center Utrecht, University College Dublin, University of Helsinki, University Hospital Würzburg, Metatissue – BioSolutions, F6S Tech, Biomotion Technologies FlexCo, Universidade Aveiro, ReGEN Biomedical, University of Otago, CO.DON GmbH, and University of Basel, the m2M platform will use an advanced bioprinting approach that combines high-precision cell deposition with scaffold structures designed to guide the fusion and remodelling of cellular aggregates.
Beyond its technical goals, the project will also promote knowledge exchange, workshops and to help advance the skills of researchers and healthcare professionals across Europe.
